Piper Sandler Reiterates a Buy on PROCEPT BioRobotics Corporation (PRCT)

​The terms people was reduced contempt the institution exceeding expectations successful its fiscal Q3 2025 results announced connected November 4. PROCEPT BioRobotics Corporation (NASDAQ:PRCT) grew its gross by 42.76% to $83.33 million, surpassing estimates by $2.56 million. Moreover, the EPS of antagonistic $0.38 besides topped the statement by $0.04. Management attributed the gross maturation to beardown request for its HYDROS Robotic System, which grew 43% year-over-year, followed by a increasing adoption of Aquablation therapy.

​Analyst Matthew O’Brien noted that the company’s Q3 show was amended than expected, and the 2025 and 2026 income forecasts are besides adjacent to Wall Street’s expectations. However, helium highlighted that the bears volition absorption connected brushed utilization show and capitalist destocking. Regardless, the expert believes these issues to beryllium temporary, caused by immoderate interior changes successful the company. The steadfast anticipates these changes to reap affirmative results for the company.

​PROCEPT BioRobotics Corporation (NASDAQ:PRCT) develops and sells the AQUABEAM Robotic System, which is simply a surgical robot that uses real-time imaging and a heat-free h2o pitchy to precisely region prostate tissue.

While we admit the imaginable of PRCT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.